ArticleTranslational lung cancer research2022

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study.

Julie Gabe Dissing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.